The Supreme Court confirmed on Thursday (13) access to a widely available abortion pill (mifepristone), rejecting a proposal from a group of anti-abortion organizations to suspend the pill’s approval by the Food and Drug Administration (FDA). In a unanimous decision, written by Justice Brett M. Kavanaugh, the court found that the plaintiffs did not have standing to challenge the FDA’s actions.
Those who oppose what a law allows others to do can always “seek greater regulatory or legislative restrictions on certain activities,” Justice Kavanaugh wrote.The case involves access
The challenge before the court focused on the changes that the FDA implemented in 2016 and 2021, expanding the distribution of the pill and facilitating patients’ ability to receive it via telemedicine and mail.
Abortion rights advocates were pleased with the decision but warned that this ruling merely maintained the status quo and that legal attacks against abortion are far from over.The case originated in Texas
A group of anti-abortion medical organizations challenged the long-standing approval of mifepristone by the FDA. In the fall of 2022, they filed a lawsuit in Amarillo, Texas.
The group – citing five studies – questioned the safety of mifepristone, which has been approved by the FDA for over two decades. However, the arguments contradict a substantial scientific record on the safety of mifepristone and another abortion medication, misoprostol.
With the Supreme Court’s decision, women can still obtain the pill within 10 weeks of pregnancy instead of seven. Similarly, the decision to allow non-physician healthcare providers to distribute the pill will remain in effect.
Source: The New York Times